Background Despite the widespread use of antenatal corticosteroids to prevent respiratory
distress syndrome in preterm infants, there is currently no consensus as to the type of …

… Author links open overlay panel Fiona C. Brownfoot MBBS a , Roxanne Hastie BBiomed
Sc a , Natalie J. Hannan B Sci, PhD a , Ping Cannon B Sci a , Laura Tuohey BSci a , Laura J. …

Preeclampsia is a major pregnancy complication where excess placental release of soluble
fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin causes maternal endothelial and …

Background Preeclampsia is associated with the placental release of soluble fms-like
tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG). These anti-angiogenic factors cause …

Preeclampsia is a disease of pregnancy associated with placental oxidative stress,
inflammation and elevated release of anti-angiogenic factors sFlt-1 and soluble endoglin. These …

Preeclampsia is a hypertensive disorder of pregnancy characterized by maternal endothelial
dysfunction and end-organ damage. The antiangiogenic factor, sFlt-1 (soluble FMS-like …

Background Preeclampsia is a major complication of pregnancy with no medical treatment.
It is associated with placental oxidative stress, hypoxia and inflammation leading to soluble …

Introduction Pre-eclampsia is a major complication of pregnancy, globally responsible for
60 000 maternal deaths per year, and far more fetal losses. There is no definitive treatment …

Introduction The discovery of new treatments that prevent or treat preeclampsia would be a
major advance. Antiangiogenic factors soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble …

Preeclampsia affects ∼2–8% of pregnancies worldwide. It is associated with increased long-term
maternal cardiovascular disease risk. This study assesses the effect of the …